AZD7442 utilization for Pre-Exposure Prophylaxis Against COVID-19 in a French Early Access Program

被引：0
|
作者：
Artaud, C. [1 ]
Majed, L. [1 ]
Fabry-Vendrand, C. [1 ]
Taylor, S. [2 ]
Ferreira, C. [3 ]
Dube, S. [2 ]
Thabut, G. [1 ]
Suau, D. [1 ]
Lahouegue, A. [1 ]
机构：
[1] AstraZeneca, Courbevoie, France
[2] AstraZeneca, Cambridge, England
[3] AstraZeneca, Wilmington, DE USA
来源：
EUROPEAN JOURNAL OF PUBLIC HEALTH | 2023年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
ckad160.97
引用
收藏
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF AZD7442 (TIXAGEVIMAB AND CILGAVIMAB) FOR PRE-EXPOSURE PROPHYLAXIS AGAINST COVID-19 IN THE IMMUNOCOMPROMISED POPULATION
    Sutton, K.
    Miller, P.
    Branscombe, N.
    Mittal, M.
    Browne, C.
    Arnetorp, S.
    Henry, T.
    Breslin, K.
    Bungey, G.
    Quint, J.
    Montgomery, H.
    VALUE IN HEALTH, 2022, 25 (12) : S168 - S168
  • [2] OPPORTUNITIES AND CHALLENGES IN LINKAGE OF EARLY ACCESS DATABASES WITH THE FRENCH NATIONAL CLAIMS DATABASE: A RWE EFFECTIVENESS STUDY OF AZD7442 FOR PRE-EXPOSURE PROPHYLAXIS AGAINST COVID-19 IN IMMUNOCOMPROMISED PATIENTS
    Luong, L.
    Jannot, A. S.
    Burdet, C.
    Majed, L.
    Fabry-Vendrand, C.
    Cerceau, T.
    Bouee, S.
    Dube, S.
    Taylor, S.
    Thabut, G.
    Artaud, C.
    VALUE IN HEALTH, 2023, 26 (12) : S509 - S509
  • [3] Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period
    Hayek, Samah
    Levy, Joseph
    Shaham, Galit
    Dagan, Noa
    Serby, Danielle
    Duskin-Bitan, Hadar
    Dube, Sabada
    Ferreira, Catia
    Livnat, Idit
    Talarico, Carla
    Taylor, Sylvia
    Venkatesan, Sudhir
    Yarden, Adva
    Balicer, Ran D.
    Netzer, Doron
    Peretz, Alon
    INFECTIOUS DISEASES AND THERAPY, 2025, 14 (02) : 433 - 445
  • [4] Efficacy and Safety of Tixagevimab-Cilgavimab (Evusheld or AZD7442) As Pre-Exposure Prophylaxis for COVID-19 Among Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Do, Quan
    Bahaj, Waled
    Chandler, Natasha
    Chao, Ju-Hsien
    Emmons, Robert V. B.
    Hegazi, Mohamed
    BLOOD, 2023, 142
  • [5] Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
    Levin, Myron J.
    Ustianowski, Andrew
    De Wit, Stephane
    Launay, Odile
    Avila, Miles
    Templeton, Alison
    Yuan, Yuan
    Seegobin, Seth
    Ellery, Adam
    Levinson, Dennis J.
    Ambery, Philip
    Arends, Rosalinda H.
    Beavon, Rohini
    Dey, Kanika
    Garbes, Pedro
    Kelly, Elizabeth J.
    Koh, Gavin C. K. W.
    Near, Karen A.
    Padilla, Kelly W.
    Psachoulia, Konstantina
    Sharbaugh, Audrey
    Streicher, Katie
    Pangalos, Menelas N.
    Esser, Mark T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (23): : 2188 - 2200
  • [6] COVID-19: Antikörperkombination AZD7442 robust wirksam bei Hochrisikopatienten
    Redaktion Facharztmagazine
    MMW - Fortschritte der Medizin, 2022, 164 (1) : 71 - 71
  • [7] SARS- CoV-2 pre-exposure prophylaxis with AZD7442 monoclonal antibodies in inborn errors of immunity with antibody defects
    Pulvirenti, F.
    Garzi, G.
    Milito, C.
    Sculco, E.
    Punziano, A.
    Maria, C.
    Antonelli, G.
    Sciannamea, M.
    Quinti, I.
    ALLERGY, 2023, 78 : 20 - 20
  • [8] Pre-exposure prophylaxis reduces risk of COVID-19
    Onuora, Sarah
    NATURE REVIEWS RHEUMATOLOGY, 2023, 19 (11) : 677 - 677
  • [9] Pre-Exposure Prophylaxis for COVID-19 in Pregnant Women
    Fesler, Melissa C.
    Stricker, Raphael B.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 279 - 284
  • [10] Pre-exposure prophylaxis reduces risk of COVID-19
    Sarah Onuora
    Nature Reviews Rheumatology, 2023, 19 : 677 - 677
12345